However, CD8+ T cells specific to self-antigen with good binding affinity may be negatively selected or self-tolerant, so POTE 272 may not be a good candidate as a cancer vaccine for the POTE protein, although this remains to be tested. This evidence concerns the gene POTED and cancer.